Title:

Immune Checkpoint Inhibitor-Induced Lymphocytic Fasciitis

Authors:

Adam Rischin¹, Ben Brady², Catriona McLean¹, Andrew JK Ostor²

¹ The Alfred Hospital, Melbourne, Australia.

² Cabrini Medical Centre, Melbourne, Australia.

Corresponding author:

Dr Adam Rischin

The Alfred Hospital, PO Box 315, Prahran VIC 3181, Australia

adamrischin@gmail.com

Ph: 9509 4244

There are no funding or financial grants to acknowledge.

Word Count: 491 words

Abstract

We present the case of a 55-year-old man who presented with bilateral forearm pain two years after nivolumab treatment for melanoma. MRI and PET scan demonstrated

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/imj.14126](https://doi.org/10.1111/imj.14126)

fasciitis, before confirmation of a florid lymphocytic infiltrate on biopsy. All symptoms resolved with immunosuppression. We discuss a unique complication of cancer immunotherapy.

A 55-year-old male with metastatic melanoma received nivolumab, an anti-programmed cell-death-protein-1 (anti-PD-1) immune checkpoint inhibitor (ICI), resulting in cancer remission. After two years he developed bilateral pain and tightness in his forearms and hands accompanied by paraesthesia then diffuse arthralgia and myalgia. Examination revealed bilateral skin tightness and forearm induration with severe limitation of finger movement but no overt synovitis. Full blood examination showed a normal white cell count with marginally raised eosinophils, $0.6 \times 10^9/L$ (0-0.5) and CRP, 30mg/L (<3); ANAs, ENAs, RF and ACPAs were not detected. Creatine kinase was normal. MRI revealed marked forearm fasciitis surrounding all muscle compartments, with no myositis (Figure 1). PET scan demonstrated remission of melanoma while confirming the fasciitis. Left forearm biopsy showed a florid lymphocytic fasciitis composed of predominantly T-cells and macrophages with scattered plasma cells and perivascular cuffing by lymphocytes in the deep subcutaneous tissue and underlying fascia (Figure 1). Eosinophils were not a feature and there was no fascial necrosis. Nivolumab was ceased and prednisolone 50mg daily commenced with methotrexate 20mg weekly. Symptoms resolved within two months apart from mild

restriction of hand movement. Prednisolone was tapered with no symptom recurrence. Repeat PET scan 10 months later showed no fasciitis or melanoma.

Immunotherapy has revolutionised the treatment of many cancers including melanoma. Prolonged survival is now a possibility due to ICIs¹. Immune-related adverse events (IRAEs) are well-recognised complications, ranging from vitiligo to life-threatening colitis, hypophysitis and pneumonitis². Arthralgia and myalgia occur in 20%¹ with other rheumatological IRAEs now increasingly recognised including de novo rheumatic diseases as well as flares of pre-existing conditions³. IRAEs identified include inflammatory arthritis, myositis, polymyalgia rheumatica, sicca syndrome and vasculitis.

We have presented a lymphocytic fasciitis secondary to ICI. Eosinophilic fasciitis after pembrolizumab (another ICI) was previously published⁴. That patient had widespread truncal and limb fasciitis, peripheral eosinophilia, $5.24 \times 10^9/L$ (<0.5) and biopsy showing dense fascial infiltrate of eosinophils, plasma cells and lymphocytes. While neither high peripheral eosinophilia nor eosinophils on biopsy are essential to a diagnosis of eosinophilic fasciitis, the absence of both in our case combined with the histopathological findings and temporal relationship to nivolumab, leave an anti-PD-1-induced lymphocytic fasciitis as the

diagnosis. Interestingly the histology showed morphology atypical for eosinophilic fasciitis with florid lymphocytic infiltration as seen in other IRAEs in connective tissues (cardiac, skeletal muscle) following nivolumab^{5,6}.

Our patient responded to prednisolone and methotrexate. As with other ICI-induced rheumatic disease, early immunosuppression appears effective however several patients have required biologics^{2,3}. Immunosuppression must be balanced against the risk of cancer progression or recurrence. Reintroduction of nivolumab was not required in this case as remission was sustained. While many of the IRAEs occur early after ICI use, rheumatological manifestations may appear late or after cessation³.

The phenomenal success of immunotherapies in oncology means their use is rising dramatically. IRAEs are therefore expected to increase in prevalence including rheumatological manifestations. Clinicians should be aware of IRAEs to optimise patient outcome with early treatment institution.

References

1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015;372(4):320-30.
2. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. *JAMA Oncology* 2016;2(10):1346-53.
3. Cappelli LC, Gutierrez AK, Bingham CO, 3rd, Shah AA. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint

Inhibitors: A Systematic Review of the Literature. *Arthritis Care Res* 2017;69(11):1751-63.

4. Khoja L, Maurice C, Chappell M, MacMillan L, Al-Habeeb AS, Al-Faraidy N, et al. Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma. *Cancer Immunol Res* 2016;4:175-8.
5. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *N Engl J Med* 2016;375(18):1749-55.
6. Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. *Cancer Sci* 2016;107(7):1055-8.

Figure Legends

Figure 1: (A, B) T2 MRI showing extensive inflammation (marked hyperintensity and enhancement) involving the fascia surrounding all of the forearm muscle compartments. Inflammation also affects the flexor and extensor tendon sheaths in the distal forearm, but the muscles are spared. (C) Forearm biopsy haematoxylin and eosin stained section showing fascia with a prominent infiltrate of lymphocytes. (D) CD3 immunoperoxidase study showing the dominant lymphocyte is a T-lymphocyte.

Abstract

We present the case of a 55-year-old man who presented with bilateral forearm pain two years after nivolumab treatment for melanoma. MRI and PET scan demonstrated fasciitis, before confirmation of a florid lymphocytic infiltrate on biopsy. All symptoms resolved with immunosuppression. We discuss a unique complication of cancer immunotherapy.

Figure 1.tiff

Title:

Immune Checkpoint Inhibitor-Induced Lymphocytic Fasciitis

Authors:

Adam Rischin¹, Ben Brady², Catriona McLean¹, Andrew JK Ostor²

¹ The Alfred Hospital, Melbourne, Australia.

² Cabrini Medical Centre, Melbourne, Australia.

Corresponding author:

Dr Adam Rischin

The Alfred Hospital, PO Box 315, Prahran VIC 3181, Australia

adamrischin@gmail.com

Ph: 9509 4244

There are no funding or financial grants to acknowledge.

Word Count: 491 words

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Rischin, A;Brady, B;McLean, C;Ostor, AJK

Title:

Immune checkpoint inhibitor-induced lymphocytic fasciitis

Date:

2018-12-01

Citation:

Rischin, A., Brady, B., McLean, C. & Ostor, A. J. K. (2018). Immune checkpoint inhibitor-induced lymphocytic fasciitis. INTERNAL MEDICINE JOURNAL, 48 (12), pp.1550-+. <https://doi.org/10.1111/imj.14126>.

Persistent Link:

<http://hdl.handle.net/11343/284902>